DOI QR코드

DOI QR Code

Development and Validation of a Robust LC-MS/MS Method for the Simultaneous Quantification of Doxifluridine and its Two Metabolites in Beagle Dog Plasma

  • Received : 2010.03.23
  • Accepted : 2010.06.19
  • Published : 2010.08.20

Abstract

A reverse-phase HPLC method with detection by mass spectrometry is described for the simultaneous determination of doxifluridine and its two active metabolites, 5-fluorouracil (5-FU) and 5-fluorouridine (5-FUrd), in beagle dog plasma. The optimal chromatographic separation was achieved on a Waters $Xterra^{(R)}$ $C_{18}$ column ($4.6{\times}250\;mm$ i.d., $5\;{\mu}m$ particle size) with a mobile phase of 0.1% formic acid in a mixture of 99% methanol and purified water (99:1, v/v). The developed method was validated in beagle dog plasma with a lowest limit of quantification of $0.05\;{\mu}g/mL$ for both doxifluridine and 5-FU, and $0.2\;{\mu}g/mL$ for 5-FUrd. Doxifluridine and its two metabolites were stable under the analysis conditions, and intra- and inter-day accuracies exceeded 92.87%, with a precision variability ${\leq}11.34%$ for each analyte. Additionally, the method for quantifying doxifluridine and its two metabolites, 5-FU and 5-FUrd, in beagle dog plasma was applied successfully to the analysis of pharmacokinetic samples.

Keywords

References

  1. Bollag, W.; Hartmann, H. R. Eur. J. Cancer 1980, 16, 427. https://doi.org/10.1016/0014-2964(80)90221-2
  2. Woo, Y. A.; Kim, G. H.; Jeong, E. J.; Kim, C. Y. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 875, 487. https://doi.org/10.1016/j.jchromb.2008.09.037
  3. Joulia, J. M.; Pinguet, F.; Grosse, P. Y.; Astre, C.; Bressolle, F. J. Chromatogr. B Biomed. Sci. Appl. 1997, 692, 427. https://doi.org/10.1016/S0378-4347(96)00518-X
  4. Ishikawa, T.; Utoh, M.; Sawada, N.; Nishida, M.; Fukase, Y.; Sekiguchi, F.; Ishitsuka, H. Biochem. Pharmacol. 1998, 55, 1091. https://doi.org/10.1016/S0006-2952(97)00682-5
  5. Schüller, J.; Cassidy, J.; Dumont, E.; Roos, B.; Durston, S.; Banken, L.; Utoh, M.; Mori, K.; Weidekamm, E.; Reigner, B. Cancer Chemother. Pharmacol. 2000, 45, 291. https://doi.org/10.1007/s002800050043
  6. Pinedo, H. M.; Peters, G. F. J. Clin. Oncol. 1988, 6, 1653. https://doi.org/10.1200/JCO.1988.6.10.1653
  7. Ishitsuka, H.; Miwa, M.; Takemoto, K.; Fukuoka, K.; Itoga, A.; Maruyama, H. B. Gann. 1980, 71, 112.
  8. Schaaf, L. J.; Dobbs, B. R.; Edwards, I. R.; Perrier, D. G. Eur. J. Clin. Pharmacol. 1988, 34, 439. https://doi.org/10.1007/BF01046699
  9. Yun, H. Y.; Bang, S. C.; Lee, K. C.; Baek, I. H.; Lee, S. P.; Kang, W.; Kwon, K. I. Talanta 2007, 71, 1553. https://doi.org/10.1016/j.talanta.2006.07.035
  10. Rosing, H.; Man, W. Y.; Doyle, E.; Bult, A.; Beijnen, J. H. J. Liq. Chromatogr. Relat. Technol. 2000, 23, 329. https://doi.org/10.1081/JLC-100101455
  11. Dams, R.; Huestis, M. A.; Lambert, W. E.; Murphy, C. M. J. Am. Soc. Mass. Spectrom. 2003, 14, 1290. https://doi.org/10.1016/S1044-0305(03)00574-9
  12. Matuszewski, B. K.; Constanzer, M. L.; Chavez-Eng, C. M. Anal. Chem. 2003, 75, 3019. https://doi.org/10.1021/ac020361s